The Journal of Menopausal Medicine (J Menopausal Med, JMM) is the official Journal of the Korean Society of Menopause (KSM), Asia Pacific Menopause Federation (APMF), and Japan Society for Menopause and Women's Health (JMWH). It is issued three times per year, on the last day of April, August, and December and is published in English. JMM is devoted to the dissemination of new knowledge concerning menopause and publishes editorials, review articles, original articles, and brief communications in the field of menopause. Manuscripts for submission to JMM should be prepared according to the following instructions for authors. JMM follows the “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (http://www.icmje.org/recommendations/)” if not otherwise described below.
All manuscripts must be submitted online through the online submission system (https://www.editorialmanager.com/jmenopausalmed/default2.aspx).This website also provides an opportunity to track the progress of your manuscript through the peer-review process. If you have any questions, please contact:
Jung Ryeol Lee, M.D., Ph.D.
The Korean Society of Menopause
Department of Obstetrics and Gynecology
73 Inchon-ro, Seongbuk-gu, Seoul 02841, Republic of Korea
Tel: +82-2-920-5310, Fax: +82-2-921-5357
All manuscripts should be prepared in strict adherence to the research and publication ethics guidelines recommended by the Council of Science Editors (CSE, http://www.councilscienceeditors.org/), International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org/), World Association of Medical Editors (WAME, http://www.wame.org/), and the Korean Association of Medical Journal Editors (KAMJE, https://www.kamje.or.kr/). The Journal of Menopausal Medicine (JMM) will follow the flowchart established by the Committee on Publication Ethics (COPE, http://publicationethics.org/resources/flowcharts) for settlement of any alleged misconduct.
Registration of the Clinical Research and Data Sharing Policy
Any research that deals with clinical trial should be registered with the primary national clinical trial registration site such as http://cris.nih.go.kr/cris/index.jsp, or other sites accredited by World Health Organization or ICMJE (http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html). This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors.” The ICMJE’s policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration, this should be reflected in the statement submitted and published with the manuscript and updated in the registry record.
Statement of Informed Consent
Copies of written informed consent and institutional review board (IRB) approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions regarding IRB approval and study conduct.
Statement of Human and Animal Rights
Clinical research should be performed in accordance with the Ethical Principles for Medical Research Involving Human Subjects, as outlined in the Helsinki Declaration of 1975 (available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-formedical-research-involving-human-subjects/). For animal subjects, the research should be performed in accordance with the guidelines set forth by the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained. Animal experiments must be reviewed by an appropriate committee (institutional animal care use committee, IACUC) for the care and use of animals.
Authorship credit should be assigned on the basis of the following: 1) substantial contributions to study conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All co-authors should meet these four conditions. If the number of authors is greater than six, there should be a list of each author’s role in the submitted paper. After the initial submission of a manuscript, any changes, whatsoever, in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from all the concerned authors. This letter must be signed by all the authors on the paper. Additionally, copyright assignment must be completed by every author.
Originality and Duplicate Publication
All submitted manuscripts should be original and should not be under consideration for publication by any other scientific journals for publication at the same time. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the explicit permission of the Editorial Board. Duplication will be checked using CrossCheck (https://app.ithenticate.com/) or eTBLAST (http://etest.vbi.vt.edu/etblast3) prior to submission. If duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutes will be informed. There may also be additional penalties for the authors. A letter of permission is required for any and all material previously published. It is the responsibility of the author to request permission from the publisher for any material being reproduced. This requirement applies to text, illustrations, figures, and tables.
It is possible to republish manuscripts if they satisfy the conditions of secondary publication set forth by the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (http://www.icmje.org/recommendations/).
Conflict of Interest
The corresponding author of an article is asked to inform the editor of the authors’ potential conflicts of interest, which might influence their interpretation of data. A potential conflict of interest should be disclosed in the cover letter even when the authors are confident that their judgments have not been influenced in preparing the manuscript. Such conflicts may be financial support or private connections to pharmaceutical companies, political pressure from interest groups, or academic problems. The disclosure form is same as the ICMJE Conflict of Interest form (http://www.icmje.org/conflicts-of-interest/). The editor will decide whether the information regarding the potential conflict will be included in the published paper. Before publishing such information, the editor will consult with the corresponding author. In particular, all sources of funding for a study should be explicitly stated. JMM requests referees to inform the editor of any conflict of interest before accepting a request to review a particular manuscript.
All manuscripts will be evaluated by three peer reviewers who are selected by the editors. The acceptance criteria for all papers are based on the quality and originality of the research and its clinical and scientific significance. An initial decision will normally be made within 4 weeks after the agreement of review by the reviewers, and the reviewers’ comments will then be sent to the corresponding author(s).
Revised manuscripts must be submitted online by the corresponding author(s). The corresponding author must indicate the alterations that have been made in response to the reviewers’ comments item by item in a response letter and submit the original file with changes tracked. Failure to resubmit the revised manuscript within 60 days after the editorial decision will be regarded as a withdrawal.
The purpose of the proof is to check for typesetting or conversion errors as well as the completeness and accuracy of the text, tables, and figures. Substantial changes in content are not permitted without the approval of the editor. Proofs must be checked carefully and corrections returned within 24 to 48 hours of receipt, as requested in the cover letter accompanying the page proofs.
All published papers become the permanent property of the Korean Society of Menopause and must not be published elsewhere without written permission. A copyright transfer form is readily available on the manuscript submission page (https://www.editorialmanager.com/jmenopausalmed/default2.aspx) and can be completed and submitted electronically. These policies follow the Creative Commons Attribution Non-Commercial License available from the following link: http://creativecommons.org/licenses/by-nc/4.0/.
The full text of JMM has been archived in PubMed Central (PMC). Authors cannot archive pre-print (i.e., pre-refereeing), but they can archive post-print (i.e., final draft post-refereeing). Authors can archive the publisher’s version/PDF.
TAdvertisements from third-party companies or resources may be accessible through our journal's web page. Our journal is a separate entity; we are not responsible or liable for any contents and advertisements available on resources linked to our web page. Advertisements are managed separately from published material, and editorial decisions remain independent from the advertisements.
Editorial board members may submit an article to the journal. When an editorial board member is listed as one of the co-authors, first author, or corresponding author of an article, this must be declared in a "Conflict of Interest” section in the manuscript. He or she will not be involved in the whole review process for clarity and transparency.
JMM allows a paper that has not conducted peer review on a preprint server such as the MedRxiv, researchsquare, and bioRxiv will not be considered as a duplicate publication, provided that the following conditions are met:
1) During submission, authors must acknowledge preprint server deposition and provide any associated accession numbers or Digital Object Identifiers (DOIs) and a link to the preprint in their manuscript and cover letter.
2) Versions of a manuscript that have been altered as a result of the peer review process may not be deposited.
3) The preprint version cannot itself have been indexed in MEDLINE or PubMed.
4) Upon publication, authors are responsible for updating the archived preprint with a DOI and link to the final published version of the article. Work that has been previously published, or is under consideration for publication in another journal, will not be considered.
5) JMM would expect the preprint to be amended after final publication to state “This is an author-created, preprint version of an article accepted for publication in the Journal of Menopausal Medicine (http://www.e-jmm.org).”
There is currently no submission fee for the JMM.
JMM publishes editorials, review articles, original articles, and brief communications
Manuscripts will not be accepted for publication unless they meet the following editorial requirements. Manuscripts must include 1) a title page, 2) a structured abstract and keywords, 3) the main text (Introduction, Materials and Methods, Results, Discussion), 4) acknowledgments, 5) references, 6) tables, and 7) figures and figure legends. Each component should begin on a new page in the following sequence.
The maximum length of a manuscript is 4,500 words of body text, excluding the abstract, references, figures, and tables. These articles are limited to 40 references.
** Addendum: The period should be erased after the address of digital object identifier (DOI).
**Authors may omit the city and country of the publishing company.
- Authors can omit the location of the company producing reagents, equipment, devices, software, etc., i.e. Gardasil 9, Merck & Co.
Editorial topics include active areas of research, fresh insights, and debates in all fields of menopause. Editorials should not exceed 2,000 words, excluding references, tables, and figures.
Reviews are invited by the editor and should be comprehensive analyses of specific topics. The manuscript for a review article should be organized in the following sequence: title page, abstract and keywords, main text (Introduction, Contents, Conclusion), acknowledgments (if necessary), references, tables, and figure legends. Manuscripts are limited to 5,000 words of text and include a 250-word summary in place of an unstructured abstract. References should not exceed 100.
Brief Communications should present focused, new clinical or investigational observations. The manuscript for a brief communication should be organized in the following sequence: title page, abstract and keywords, main text, acknowledgments (if necessary), references, tables, and figure legends. The manuscript should not exceed 2,000 words and the number of references is limited to 15. The abstract should be unstructured and should not exceed 250 words.
Notice: These recently revised instructions for authors will be applied beginning with the April 2023 issue.
대한폐경학회 은(는) 고객센터, 고객상담 등을 위해 아래와 같은 개인정보를 수집하고 있습니다.
대한폐경학회 은(는) 다음과 같은 방법으로 개인정보를 수집합니다.
대한폐경학회 은(는) 수집한 개인정보를 다음의 목적을 위해 활용합니다.
대한폐경학회 은(는) 이용자의 개인정보를 원칙적으로 외부에 제공하지 않습니다. 다만, 아래의 경우에는 예외로 합니다.
대한폐경학회 은(는) 고객님의 동의없이 고객님의 개인정보 취급을 외부 업체에 위탁하지 않습니다.
향후 그러한 필요가 생길 경우, 위탁 대상자와 위탁 업무 내용에 대해 고객님에게 통지하고 필요한 경우 사전 동의를 받도록 하겠습니다.
원칙적으로, 개인정보 수집 및 이용목적이 달성된 후에는 해당 정보를 지체없이 파기합니다. 단, 다음의 정보에 대해서는 아래의 이유로 명시한 기간 동안 보존합니다.
<내부 방침에 의한 정보보유 사유>
대한폐경학회 은(는) 원칙적으로 개인정보 수집 및 이용목적이 달성된 후에는 해당 정보를 지체없이 파기합니다. 파기절차 및 방법은 다음과 같습니다.
이용자 및 법정 대리인은 언제든지 등록되어 있는 자신 혹은 당해 만14세 미만 아동의 개인정보를 조회하거나 수정할 수 있으며 가입해지를 요청할 수도 있습니다.
이용자 혹은 만 14세 미만 아동의 개인정보 조회·수정을 위해서는 ‘개인정보변경’(또는 ‘회원정보수정’ 등)을, 가입해지(동의철회)를 위해서는 “회원탈퇴”를 클릭하여 본인 확인 절차를 거치신 후 직접 열람, 정정 또는 탈퇴가 가능합니다.
혹은 개인정보관리책임자에게 서면, 전화 또는 이메일로 연락하시면 지체없이 조치하겠습니다.
귀하가 개인정보의 오류에 대한 정정을 요청하신 경우에는 정정을 완료하기 전까지 당해 개인정보를 이용 또는 제공하지 않습니다. 또한 잘못된 개인정보를 제3자에게 이미 제공한 경우에는 정정 처리결과를 제3자에게 지체없이 통지하여 정정이 이루어지도록 하겠습니다.
혹은 개인정보관리책임자에게 서면, 전화 또는 이메일로 연락하시면 지체없이 조치하겠습니다.
대한폐경학회 은(는) 이용자 혹은 법정 대리인의 요청에 의해 해지 또는 삭제된 개인정보는 “대한폐경학회 이(가) 수집하는 개인정보의 보유 및 이용기간”에 명시된 바에 따라 처리하고 그 외의 용도로 열람 또는 이용할 수 없도록 처리하고 있습니다.
대한폐경학회 은(는) 귀하의 정보를 수시로 저장하고 찾아내는 ‘쿠키(cookie)’, ‘세션(session)’ 등 개인정보를 자동으로 수집하는 장치를 설치•운용합니다. 쿠키란 대한폐경학회 의 웹사이트를 운영하는데 이용되는 서버가 귀하의 브라우저에 보내는 아주 작은 텍스트 파일로서 귀하의 컴퓨터 하드디스크에 저장됩니다.
대한폐경학회 은(는) 다음과 같은 목적을 위해 쿠키 등을 사용합니다.
귀하께서는 대한폐경학회 의 서비스를 이용하시며 발생하는 모든 개인정보보호 관련 민원을 개인정보관리책임자 혹은 담당부서로 신고하실 수 있습니다. 회사는 이용자들의 신고사항에 대해 신속하게 충분한 답변을 드릴 것입니다.
공고일자 : 2009년 07월 09일
시행일자 : 2009년 07월 09일